Este articulo es un Preprint
Los preprints son informes de investigación preliminares que no han sido certificados por revisión por pares. No deben considerarse para guiar la práctica clínica o los comportamientos relacionados con la salud y no deben publicarse en los medios como información establecida.
Los preprints publicados en línea permiten a los autores recibir comentarios rápidamente, y toda la comunidad científica puede evaluar de forma independiente el trabajo y responder adecuadamente. Estos comentarios se publican junto con los preprints para que cualquiera pueda leer y servir como una revisión pospublicación.
Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Loreto, Peru.
Preprint
en Inglés
| medRxiv
| ID: ppmedrxiv-21249913
ABSTRACT
BackgroundDetection of SARS-CoV-2 antibodies among people at risk is critical for understanding both the prior transmission of COVID-19 and vulnerability of the population to the continuing transmission and, when done serially, the intensity of ongoing transmission over an interval in a community. In this study, we estimated the seroprevalence of COVID-19 in a representative population-based cohort of Iquitos, one of the regions with the highest mortality rates from COVID-19 in Peru, where a devastating number of cases occurred in March 2020. MethodsWe conducted a population-based study of transmission tested each participant using the COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech and used survey analysis methods to estimate seroprevalence accounting for the sampling design effect and test performance characteristics. Here we report results from the baseline (13 to 18 July 2020) and the first month of follow-up (13 to 18 August 2020) study. FindingsWe enrolled a total of 716 participants and estimated seroprevalence of 70.0% (95% CI 67.0%-73.4%), a test-re-test positivity of 65% (95% CI 61.0%-68.3%), and an incidence of new exposures of 1.8% (95% CI 0.9%-3.2%) data that suggest that transmission is ongoing but is occurring at low levels. We observed significant differences in the seroprevalence between age groups, with participants 18 to 29 years of age having lower seroprevalence than children <12 years of age (Prevalence ratio =0.85 [PR]; 95% CI 0.73 - 0.98), suggesting that children were not refractory to infection in this setting. InterpretationIquitos demonstrates one of the highest rates of seroprevalence of COVID-19 worldwide. Current data shows a limited case burden in Iquitos for the past seven months and suggests that these levels are sufficient to provide significant but incomplete herd immunity. FundingDireccion Regional de Salud de Loreto, DIRESA, Loreto, Peru
cc_by_nd
Texto completo:
Disponible
Colección:
Preprints
Base de datos:
medRxiv
Tipo de estudio:
Cohort_studies
/
Experimental_studies
/
Estudio observacional
/
Estudio pronóstico
/
Rct
Idioma:
Inglés
Año:
2021
Tipo del documento:
Preprint